Diabetes Drugs Show Promise for Slowing Frailty in Older Adults
New research suggests certain diabetes medications may help older adults maintain strength and independence longer.
20 articles
New research suggests certain diabetes medications may help older adults maintain strength and independence longer.
A 2025 review maps the molecular drivers of cardiac aging and evaluates drugs, CRISPR, stem cells, and lifestyle as countermeasures.
Real-world study of 1,559 octogenarians finds SGLT2 inhibitors reduce all-cause death by 42% and heart failure rehospitalization by 31% with no increase in adverse events.
A new review examines how drugs that clear senescent cells could transform treatment of age-related cardiovascular disease.
New research reveals GLP-1 receptor agonists could significantly reduce cardiovascular risk in broader patient populations.
New research shows citrate supplementation restores blood vessel function and extends lifespan by improving mitochondrial health.
In obese middle-aged mice, reducing dietary protein—without cutting calories—reversed cardiac inflammation and remodeling via AMPK-ULK1 mitophagy.
GLP-1 drug semaglutide demonstrates potential benefits for Alzheimer's patients following major clinical trial results.
New research reveals how obesity-driven cellular senescence creates a toxic environment that fuels breast cancer development and progression.
Scientists reveal CFTR protein prevents cardiomyocyte senescence by reducing mitochondrial oxidative stress via a newly discovered deubiquitination pathway.
Dive deep into the molecular mechanisms of vascular aging and explore cutting-edge interventions — from senolytic therapies and nitric oxide restoration to exercise-induced remodeling and emerging pharmacological approaches — that are redefining what's possible in cardiovascular longevity.
Dr. Jamnadas reveals which foods can protect against AGEs, the hidden compounds in our diet that speed up aging and disease.
A pill-form GLP-1 receptor agonist significantly reduced multiple cardiovascular risk markers in both T2D and obesity patients over 26–36 weeks.
New research reveals how dopamine antagonists could prevent dangerous hypoglycemia unawareness in diabetic patients.
A 2025 review maps the molecular mechanisms driving cardiovascular aging—from inflammaging to ECM remodeling—and outlines emerging therapies.
New evidence suggests oral semaglutide sustains long-term improvements in key CVD risk factors, expanding its role beyond diabetes management.
A major review reveals how SGLT2 inhibitors protect the heart, kidneys, and metabolism through at least seven distinct biological mechanisms.
Dr. Jamnadas reveals how cooking methods and food choices create AGEs that damage your body and accelerate aging at the cellular level.
A comprehensive review reveals tirzepatide improves blood pressure, lipids, liver fat, kidney function, and slashes 10-year cardiovascular risk by up to 23.5%.
Scientists found that boosting ApoM levels helps clear harmful cholesterol deposits that cause age-related vision loss and heart problems.